Capecitabine efficacy after cycline-dependent-kinase 4/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer.
Fiche publication
Date publication
juin 2023
Journal
Cancer treatment and research communications
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry, Dr BENDER Laura
Tous les auteurs :
Bender L, Pflumio C, Trensz P, Pierard L, Kalish M, Fischbach C, Petit T
Lien Pubmed
Résumé
The combination of endocrine treatment with cycline-dependent-kinase 4/6 inhibitor is the new standard of treatment in hormone receptor-positive HER2 negative metastatic breast cancer. The optimal subsequent treatment after CDK4/6 inhibitor remain unclear. As recommended by standard guidelines, capecitabine, an oral chemotherapy is a therapeutic option in endocrine resistant metastatic breast cancer. The objective of this study was to evaluate capecitabine efficacy after disease progression under combination of ET and CDK4/6 inhibitor in a hormone receptor positive metastatic breast cancer population.
Mots clés
Breast cancer, Capecitabine, Cycline-dependant kinase inhibition
Référence
Cancer Treat Res Commun. 2023 06 25;36:100738